Your browser doesn't support javascript.
Cefepime/tazobactam compared with other tazobactam combinations against problem Gram-negative bacteria.
Mushtaq, Shazad; Garello, Paolo; Vickers, Anna; Woodford, Neil; Livermore, David M.
  • Mushtaq S; Antimicrobial Resistance and Healthcare Associated Infections Reference Unit, National Infection Service, Public Health England, London, UK.
  • Garello P; Antimicrobial Resistance and Healthcare Associated Infections Reference Unit, National Infection Service, Public Health England, London, UK.
  • Vickers A; Antimicrobial Resistance and Healthcare Associated Infections Reference Unit, National Infection Service, Public Health England, London, UK.
  • Woodford N; Antimicrobial Resistance and Healthcare Associated Infections Reference Unit, National Infection Service, Public Health England, London, UK.
  • Livermore DM; Antimicrobial Resistance and Healthcare Associated Infections Reference Unit, National Infection Service, Public Health England, London, UK; Norwich Medical School, University of East Anglia, Norwich, UK. Electronic address: d.livermore@uea.ac.uk.
Int J Antimicrob Agents ; 57(5): 106318, 2021 May.
Article in English | MEDLINE | ID: covidwho-1131354
ABSTRACT

OBJECTIVES:

Piperacillin/tazobactam has long been a broad-spectrum 'workhorse' antibiotic; however, it is compromised by resistance. One response is to re-partner tazobactam with cefepime, which is easier to protect, being less ß-lactamase labile, and to use a high-dose and prolonged infusion. On this basis, Wockhardt are developing cefepime/tazobactam (WCK 4282) as a 2+2 g q8h combination with a 90-min infusion.

METHODS:

The activity of cc cefepime/tazobactam was assessed, with other tazobactam combinations as comparators, against 1632 Enterobacterales, 745 Pseudomonas aeruginosa and 450 other non-fermenters, as submitted to the UK National Reference Laboratory. These were categorised by carbapenemase-gene detection and interpretive reading of phenotypes, with MICs determined by British Society for Antimicrobial Chemotherapy agar dilution.

RESULTS:

Although higher breakpoints may be justifiable, based on the pharmacodynamics, the results were reviewed against current cefepime criteria. On this basis, cefepime/tazobactam was broadly active against Enterobacterales with AmpC enzymes and extended-spectrum ß-lactamases (ESBLs), even when they had ertapenem resistance, suggesting porin loss. At 8+8 mg/L, activity extended to > 90% of Enterobacterales with OXA-48 and KPC carbapenemases, although the MICs for KPC producers belonging to the international Klebsiella pneumoniae ST258 lineage were higher; metallo-ß-lactamase producers remained resistant. Cefepime/tazobactam was less active than ceftolozane/tazobactam against Pseudomonas aeruginosa with AmpC de-repression or high-level efflux but achieved wider antipseudomonal coverage than piperacillin/tazobactam. Activity against other non-fermenters was species-specific.

CONCLUSION:

Overall, cefepime/tazobactam had a spectrum exceeding those of piperacillin/tazobactam and ceftolozane/tazobactam and resembling or exceeding that of carbapenems. Used as a 'new-combination of old-agents' it has genuine potential to be 'carbapenem-sparing'.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Cephalosporins / Cefepime / Piperacillin, Tazobactam Drug Combination / Tazobactam / Gram-Negative Bacteria / Anti-Bacterial Agents Type of study: Diagnostic study Limits: Humans Language: English Journal: Int J Antimicrob Agents Year: 2021 Document Type: Article Affiliation country: J.ijantimicag.2021.106318

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Cephalosporins / Cefepime / Piperacillin, Tazobactam Drug Combination / Tazobactam / Gram-Negative Bacteria / Anti-Bacterial Agents Type of study: Diagnostic study Limits: Humans Language: English Journal: Int J Antimicrob Agents Year: 2021 Document Type: Article Affiliation country: J.ijantimicag.2021.106318